EN
Home/Answers/Kidney disease
ALLAll countries Side effects and safety

Can you take tirzepatide or semaglutide with kidney disease?

What we checked18 sources, each one opened and linked to the sentence it supportsLast checked Nov 16, 2026 · Next review due Nov 16, 2027 · How we write
The short answer

Kidney disease alone does not rule out tirzepatide (Mounjaro, Zepbound) or semaglutide (Ozempic, Wegovy). Their labels give no lower dose for mild or moderate disease, and some advise against use in kidney failure. The labelled risk is sudden kidney injury from dehydration. In type 2 diabetes with kidney disease, semaglutide slowed kidney decline in the FLOW trial.

What do the labels say about weak kidneys?

The US and EU labels for tirzepatide and semaglutide give no lower dose for people with mild or moderate kidney disease.1,2,3,4,5,6

The US Ozempic, Mounjaro and Zepbound labels recommend no dose change for any level of kidney impairment, kidney failure included, and report no meaningful change in drug levels in these people.1,2,3

The EU labels differ for severe disease, where the EU Ozempic label gives no dose change and reports little experience in end-stage kidney disease.4 The EU Mounjaro label advises caution in severe and end-stage disease, where experience is limited.6 The EU Wegovy label does not recommend semaglutide when eGFR, the usual measure of kidney filtering, is below 30, or in end-stage disease.5

How can these medicines harm the kidneys?

The US and EU labels warn that nausea, vomiting or diarrhoea can cause dehydration, which can suddenly damage the kidneys.1,2,4,6

Doctors call this acute kidney injury. The US labels describe cases reported since launch, some needing dialysis, mostly in people who had become dehydrated.1,2,3 In two weight-loss trials, the US Zepbound label reports acute kidney injury in 0.5% of people on tirzepatide and 0.2% on placebo.3

The US labels advise kidney checks in people with these stomach side effects, especially when starting or raising the dose.1,2 The EU labels say people should take precautions against losing fluid.4,6 The NHS lists dehydration, and long-term use of diuretics or ACE inhibitors, among the causes of acute kidney injury.17

What do the kidney trials show?

In the FLOW trial, semaglutide 1 mg weekly lowered serious kidney outcomes and heart deaths in adults with type 2 diabetes and kidney disease.1,7

FLOW gave 3,533 adults semaglutide or a placebo (dummy injection), with a median follow-up of 41 months.1 It enrolled people with an eGFR of 25 to 75, so it did not test people on dialysis.1 It left out people with inherited or autoimmune kidney diseases, such as polycystic kidney disease.1

The main outcome, a halving of kidney function, kidney failure, or death from kidney or heart causes, happened to 18.7% on semaglutide and 23.2% on placebo, and semaglutide slowed the yearly fall in eGFR.1,7 Long-term dialysis or a transplant, counted alone, was 4.9% against 5.7%, a gap that could be chance.1 The benefit was not clear in people already taking an SGLT2 inhibitor, though few of them had events.1

Novo Nordisk, the maker, funded FLOW.7 The UK Ozempic label says the trial found no new serious side effects, though it collected only serious and selected side effects.9

The US Ozempic label lists this kidney use, at 1 mg weekly.1 The EU Ozempic label covers type 2 diabetes and gives the kidney results as trial data.4 The US Mounjaro label lists no kidney use.2

A 2025 review pooled 15 tirzepatide trials in 14,471 people, lasting 26 to 72 weeks. Acute kidney injury was not clearly more common than on placebo, and albumin in the urine fell more on 10 mg and 15 mg. The authors rated most of this evidence low or very low certainty.8

What do people on GLP-1 medicines report about kidney disease?

From public patient forums: 21 Reddit threads in r/Zepbound, r/Semaglutide, r/mounjarouk, r/Ozempic, r/glp1 and r/Mounjaro, read from October 2025 to October 2026. Personal reports, not medical evidence.

What people describe

  • Matches the label Many describe kidney test results getting worse after starting, and some found another cause, such as an infection or a supplement. The US labels report sudden kidney injury on these medicines, mostly in people who became dehydrated.1,2
  • Matches the label Several put a low reading down to drinking too little, and say it recovered after they drank more and retested. The labels link most reported kidney injury to dehydration.1,2
  • Matches the trial Many describe kidney results that held steady or improved on treatment, and some say their doctor credited weight loss or blood pressure control. In FLOW, semaglutide slowed the yearly fall in kidney function in people with type 2 diabetes and kidney disease; it did not show improvement.1
  • Matches the label Many say a GP or kidney specialist prescribed a GLP-1 medicine alongside kidney disease, sometimes for people on dialysis. The US Ozempic and Mounjaro labels set no lower dose for kidney impairment, kidney failure included.1,2 The EU Wegovy label does not recommend semaglutide in end-stage disease.5

Advice people share

  • Matches the label Many advise drinking more on purpose, aiming for pale pee, with extra care during vomiting or diarrhoea. The US Ozempic label advises precautions against fluid loss, and the NHS suggests drinking enough to keep pee pale.1,17
  • Matches the label Several with kidney disease say to watch for vomiting, diarrhoea and dehydration. The US Mounjaro label advises kidney checks in people with kidney impairment who have severe stomach side effects.2

In your country

Every Ozempic label we opened, from the US, EU, UK, Australia and Canada, carries the dehydration warning.1,4,9,11,14 Labels differ on severe kidney disease and kidney failure, and on whether semaglutide has a kidney use.

Australia

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill treated as not approved). Semaglutide tablets, diabetes: Rybelsus approved; whether supplied not confirmed.

Label: The Australian Ozempic label lists a use in type 2 diabetes with kidney disease, to slow the decline in kidney function.11 The Australian Wegovy label does not recommend it in end-stage kidney disease, and the Mounjaro label advises caution in severe and end-stage disease.12,13

Emergency number: 000

GLP-1 side effects and risks (Australia)

Canada

Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen, Zepbound. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Semaglutide Injection (Dr. Reddy’s; shortage reported Jul 2026, lots recalled Aug 2026); Apo-Semaglutide (one lot recalled Aug 2026). Semaglutide tablets, weight: none (no oral Wegovy in Health Canada’s drug database). Semaglutide tablets, diabetes: Rybelsus. Semaglutide approved but not marketed: Sevmia, Poviztra, Plosbrio, Aspen-Semaglutide, Semaglutide Injection (Aspen), Sandoz Semaglutide.

Label: The Canadian Ozempic label lists a kidney use in adults with type 2 diabetes and kidney disease.14 The Canadian Wegovy and Zepbound labels do not recommend them in end-stage kidney disease.15,16

Emergency number: 911

GLP-1 side effects and risks (Canada)

France

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill not sold in France). Semaglutide tablets, diabetes: none found (Rybelsus not in France’s medicines database).

Label: The answer above applies.

Emergency number: 15 or 112

Effets secondaires des GLP-1 (France)

Germany

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy Tablette. Semaglutide tablets, diabetes: Rybelsus.

Label: The answer above applies.

Emergency number: 112

Nebenwirkungen der Abnehmspritze (Deutschland)

India

Sold as: Tirzepatide: Mounjaro, Yurpeak. Semaglutide injection, weight: Wegovy; Poviztra; Noveltreat. Semaglutide injection, diabetes: Ozempic; Obeda (Dr Reddy’s; recalled Jul 2026 over an active-ingredient impurity; on 23 Oct 2026 the company said it planned to relaunch in Nov; resumption not confirmed at 8 Nov 2026; distributors told Reuters it may be discontinued); Sematrinity; GLIPIQ; Semalix (batches recalled Jul 2026); Semanat; Semafull. Semaglutide injection, diabetes and weight: Semaglyn; Mashema; Alterme; Semasize; Obesema; Hepaglide. Semaglutide, diabetes and weight (form not confirmed): Obeda Pro; Obeda Plus (Dr Reddy’s, made by Hetero Labs; in the market from late Jul 2026). Semaglutide injection, use not confirmed: Semanext; Livarise; Sundae. Semaglutide, form and use not confirmed: Samakind; Usema (batches recalled). Semaglutide tablets, weight: not confirmed. Semaglutide tablets, diabetes: Rybelsus; Sembolic; Obeda (tablets not part of the Jul 2026 recall).

Label: We found no public Indian label. This page relies on the US and EU labels.

Emergency number: 112

GLP-1 side effects and risks (India)

Saudi Arabia

Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Tasylev; Lugyda; Glucentra. Semaglutide tablets, weight: none (Wegovy pill not registered). Semaglutide tablets, diabetes: Rybelsus.

Label: We could not open a Saudi label. This page relies on the US and EU labels.

Emergency number: 997 or 911

الأعراض الجانبية لأدوية GLP-1 (السعودية)

United Arab Emirates

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Rybelsus.

Label: We could not open a UAE label. This page relies on the US and EU labels.

Emergency number: 998 for an ambulance, or 999

GLP-1 side effects and risks (UAE)

United Kingdom

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy tablets (authorised 11 Jun 2026; retail sale not confirmed). Semaglutide tablets, diabetes: Rybelsus.

Label: The UK Wegovy label needs no dose change in severe kidney disease and does not recommend it only in end-stage disease, so the EU cut-off of eGFR 30 does not appear.10

Emergency number: 999

GLP-1 side effects and risks (UK)

United States

Sold as: Tirzepatide: Zepbound, Mounjaro. Semaglutide injection, weight: Wegovy, including Wegovy HD 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Ozempic tablets; Rybelsus (being discontinued).

Label: The answer above applies.

Emergency number: 911

GLP-1 side effects and risks (US)

Get help now: call your local emergency number if someone who has been losing fluids feels faint, is very drowsy, breathes fast and weakly, or has pale, cool, clammy skin. These can be signs of shock, which dehydration can cause.18 Emergency numbers: 911 in the US and Canada, 999 in the UK, 998 or 999 in the UAE, 000 in Australia, 112 in India and Germany, 15 or 112 in France, 997 or 911 in Saudi Arabia.

Contact your prescriber or a doctor right away if you are peeing a lot less than usual, feel very thirsty, or feel confused or sleepy. These can be signs of acute kidney injury.17 The US Ozempic label also says to report nausea, vomiting or diarrhoea that won't stop.1

Read the full picture

Related questions

Did this answer your question?

Sources

  1. Novo Nordisk. Ozempic (semaglutide) injection, US prescribing information. US label. Sections 1, 2, 5.6, 8.6, 14.3 (Table 10), 17. dailymed.nlm.nih.gov
  2. Eli Lilly. Mounjaro (tirzepatide) US prescribing information. US label. Sections 1, 5.5, 8.6. pi.lilly.com
  3. Eli Lilly. Zepbound (tirzepatide) US prescribing information. US label. Sections 5.3, 6.1, 8.6. pi.lilly.com
  4. European Medicines Agency. Ozempic: summary of product characteristics. EU label. Sections 4.1, 4.2, 4.4. ema.europa.eu
  5. European Medicines Agency. Wegovy: summary of product characteristics. EU label. Section 4.2. ema.europa.eu
  6. European Medicines Agency. Mounjaro: summary of product characteristics. EU label. Sections 4.2, 4.4. ema.europa.eu
  7. Perkovic V et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med 2024;391:109-21. Funded by Novo Nordisk. doi:10.1056/NEJMoa2403347 · PMID 38785209
  8. Kamrul-Hasan A et al. Renal effects and safety of tirzepatide in subjects with and without diabetes: a systematic review and meta-analysis. World J Diabetes 2025;16(2):101282. PMC11718474
  9. Novo Nordisk. Ozempic 1 mg solution for injection: summary of product characteristics. UK label. Section 4.8 (kidney outcomes trial). medicines.org.uk
  10. Novo Nordisk. Wegovy 2.4 mg FlexTouch: summary of product characteristics. UK label. Section 4.2. medicines.org.uk
  11. Novo Nordisk. Ozempic Product Information. Australian label. Sections 4.1, 4.2. medsinfo.com.au
  12. Novo Nordisk. Wegovy Product Information. Australian label. Section 4.2. medsinfo.com.au
  13. Eli Lilly. Mounjaro Product Information. Australian label. Section 4.2. medsinfo.com.au
  14. Novo Nordisk. Ozempic Product Monograph. Canadian label. Section 1. pdf.hres.ca
  15. Novo Nordisk. Wegovy Product Monograph. Canadian label. Section 4. pdf.hres.ca
  16. Eli Lilly. Zepbound Product Monograph. Canadian label. Section 7.1.6. pdf.hres.ca
  17. NHS (UK). Acute kidney injury (AKI). nhs.uk
  18. American College of Emergency Physicians. Shock: know when to go to the ER. emergencyphysicians.org

Last checked Nov 16, 2026 · Next review due Nov 16, 2027 · Report an error

How this answer was made. Written by the GLP Guidebook team from the sources above, all checked on Nov 16, 2026. The “What people report” section summarises public patient forum posts we read; it is not medical evidence, and we never pass on advice that goes against the label. It’s general information, not medical advice. Talk to a doctor, pharmacist or other licensed prescriber before starting, stopping or changing any medicine. In an emergency, call your local emergency number. How we write